Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Consulting agrmnt
Appointed director
Notes underwriting agrmnt
Director departure
Bone Biologics Corp (BBLG) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 ARS Form ARS - Annual Report to Security Holders:
08/03/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/03/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/05/2023 8-K Other Events  Interactive Data
06/16/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNDERWRITING AGREEMENT between BONE BIOLOGICS CORPORATION and EF HUTTON, DIVISION OF BENCHMARK INVESTMENTS, LLC New York, New York June 14, 2023 EF HUTTON, division of Benchmark Investments, LLC as Representative of the several Underwriters named on Schedule I hereto 590 Madison Avenue, 39 th Floor New York, New York 10022",
"Bone Biologics Prices $5.0 Million Underwritten Public Offering"
06/15/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
06/13/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
06/06/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
05/19/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/11/2023 DEF 14C Form DEF 14C - Other definitive information statements:
05/01/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
05/01/2023 PRE 14C Form PRE 14C - Other preliminary information statements:
03/29/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
03/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/08/2023 4 Angle Siddhesh Rajendra (Director) has filed a Form 4 on Bone Biologics Corp
Txns: Granted 36,845 options to buy @ $1.61, valued at $59.3k
03/08/2023 4 Stroever Bruce (Director) has filed a Form 4 on Bone Biologics Corp
Txns: Granted 36,845 options to buy @ $1.61, valued at $59.3k
03/08/2023 4 Frelick Jeff (CEO) has filed a Form 4 on Bone Biologics Corp
Txns: Granted 37,750 options to buy @ $0.24, valued at $9.1k
03/08/2023 4 Lucera Erick (Director) has filed a Form 4 on Bone Biologics Corp
Txns: Granted 36,845 options to buy @ $1.61, valued at $59.3k
03/08/2023 4 Walsh Deina H (CFO) has filed a Form 4 on Bone Biologics Corp
Txns: Granted 18,875 options to buy @ $0.24, valued at $4.5k
02/14/2023 SC 13G Walleye Capital LLC reports a 5.4% stake in Bone Biologics Corporation
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/04/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
12/21/2022 8-K Quarterly results
11/21/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/25/2022 8-K Quarterly results
10/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM OF SERIES A WARRANT BONE BIOLOGICS CORPORATION SERIES A COMMON STOCK PURCHASE WARRANT Warrant Shares: _______ Initial Exercise Date: October 12, 2022 THIS SERIES A COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on October 12, 2027 but not thereafter, to subscribe for and purchase from Bone Biologics Corporation, a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant shall initially be issued and maintained in th...",
"FORM OF SERIES B WARRANT BONE BIOLOGICS CORPORATION SERIES B COMMON STOCK PURCHASE WARRANT Warrant Shares: _______ Initial Exercise Date: October 12, 2022 THIS SERIES B COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on October 12, 2027 but not thereafter, to subscribe for and purchase from Bone Biologics Corporation, a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant shall initially be issued and maintained in th...",
"FORM OF SERIES C WARRANT BONE BIOLOGICS CORPORATION SERIES C COMMON STOCK PURCHASE WARRANT Warrant Shares: _______ Initial Exercise Date: October 12, 2022 THIS SERIES C COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on October 12, 2027 but not thereafter, to subscribe for and purchase from Bone Biologics Corporation, a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant shall initially be issued and maintained in th...",
"Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering"
10/11/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BONE BIOLOGICS CORPORATION UNDERWRITING AGREEMENT 3,777,778 Units Consisting of 3,777,778 Shares of Common Stock, And 3,777,778 Series A Warrants to Purchase 3,777,778 Shares of Common Stock And 3,777,778 Series B Warrants to Purchase 3,777,778 Shares of Common Stock And 3,777,778 Series C Warrants to Purchase 3,777,778 Shares of Common Stock October 7, 2022 WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson Street, Ste 1410 Jersey City, NJ 07311",
"WARRANT AGENT AGREEMENT This Warrant Agent Agreement , dated as of October 7, 2022 between Bone Biologics Corp., a company incorporated under the laws of the State of Delaware , and Equiniti Trust Company, a limited trust company organized under the laws of the State of New York . WHEREAS, pursuant to the terms of that certain Underwriting Agreement , dated October 7, 2022, by and among the Company and WallachBeth Capital, LLC, as representatives of the underwriters set forth therein, the Company is engaged in a public offering of up to 3,777,778 Units, each Unit consisting of: one share of common stock, par value $0.001 per share of the Company; one Series A Warrant to purchase one share of Common Stock ; one Series B Warrant to purchase one share of Common Stock and; one Series C Warrant...",
"Bone Biologics Prices $5,100,000 Underwritten Public Offering"
10/11/2022 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
10/07/2022 S-1MEF Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]:
10/07/2022 S-1MEF Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]:
10/07/2022 EFFECT Form EFFECT - Notice of Effectiveness:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy